These data confirm that, in addition to inhibiting PARP catalytic function, the ability of Niraparib to promote cell death in PDAC and ovarian cancer cells regardless of BRCA status is partially mediated by its inhibitory effects on pSTAT3. Here, PARP1 is linked to ovarian cancer.